哪些人应该接受炎症性肠病的生物治疗？：采用个性化方法的理论依据。
Who should receive biologic therapy for IBD?: The rationale for the application of a personalized approach.
作者信息
Jones Jennifer, Peña-Sánchez Juan Nicolás
机构信息
Department of Medicine, University of Saskatchewan, 108 Hospital Drive, Saskatoon, Saskatchewan S7N0W8, Canada.
Department of Medicine, School of Public Health, University of Saskatchewan, 104 Clinic Place, Saskatoon, Saskatchewan S7N 5E5, Canada.
出版信息
Gastroenterol Clin North Am. 2014 Sep;43(3):425-40. doi: 10.1016/j.gtc.2014.05.004.
The therapeutic approach in inflammatory bowel disease has evolved to target end-organ inflammation to heal intestinal mucosa and avoid structural damage. Objective therapeutic monitoring is required to achieve this goal. Earlier intervention with biologic therapy has been shown, indirectly, to be associated with higher clinical response and remission rates. A personalized approach to risk stratification with consideration of key clinical factors and inflammatory biomarker concentrations is recommended when deciding whether or not to start a patient on biologic therapy.
炎症性肠病的治疗方法已发展为针对终末器官炎症，以治愈肠道黏膜并避免结构损伤。实现这一目标需要客观的治疗监测。间接证据表明，早期采用生物疗法干预与更高的临床缓解率相关。在决定是否开始对患者进行生物治疗时，建议采用个性化的风险分层方法，同时考虑关键临床因素和炎症生物标志物浓度。
Zotero 插件